S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Shelling kills 1 in Ukraine; Russia wants nuke plant pledges
The Day of Financial Reckoning Is Near (Ad)
High oil prices help Saudi Aramco earn $88B in first half
Ship carrying grain for hungry Ethiopia leaves Ukraine
Saudi Aramco's profits already $88B as oil prices stay high
“No Historic Crash Is Coming, What’s NEXT, Is Much Worse…” (PhD Economist) (Ad)
Saudi oil company Aramco's half-year profits reach close to $88 billion after posting a 90% surge in second quarter
Average US gasoline price falls 45 cents to $4.10 per gallon
'Everyone's Got a Story of How the Healthcare System Has Fallen Short.' This Founder Is on a Mission to Change That.
The Financial Day of Reckoning Has Begun (Ad)
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Shelling kills 1 in Ukraine; Russia wants nuke plant pledges
The Day of Financial Reckoning Is Near (Ad)
High oil prices help Saudi Aramco earn $88B in first half
Ship carrying grain for hungry Ethiopia leaves Ukraine
Saudi Aramco's profits already $88B as oil prices stay high
“No Historic Crash Is Coming, What’s NEXT, Is Much Worse…” (PhD Economist) (Ad)
Saudi oil company Aramco's half-year profits reach close to $88 billion after posting a 90% surge in second quarter
Average US gasoline price falls 45 cents to $4.10 per gallon
'Everyone's Got a Story of How the Healthcare System Has Fallen Short.' This Founder Is on a Mission to Change That.
The Financial Day of Reckoning Has Begun (Ad)
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Shelling kills 1 in Ukraine; Russia wants nuke plant pledges
The Day of Financial Reckoning Is Near (Ad)
High oil prices help Saudi Aramco earn $88B in first half
Ship carrying grain for hungry Ethiopia leaves Ukraine
Saudi Aramco's profits already $88B as oil prices stay high
“No Historic Crash Is Coming, What’s NEXT, Is Much Worse…” (PhD Economist) (Ad)
Saudi oil company Aramco's half-year profits reach close to $88 billion after posting a 90% surge in second quarter
Average US gasoline price falls 45 cents to $4.10 per gallon
'Everyone's Got a Story of How the Healthcare System Has Fallen Short.' This Founder Is on a Mission to Change That.
The Financial Day of Reckoning Has Begun (Ad)
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Shelling kills 1 in Ukraine; Russia wants nuke plant pledges
The Day of Financial Reckoning Is Near (Ad)
High oil prices help Saudi Aramco earn $88B in first half
Ship carrying grain for hungry Ethiopia leaves Ukraine
Saudi Aramco's profits already $88B as oil prices stay high
“No Historic Crash Is Coming, What’s NEXT, Is Much Worse…” (PhD Economist) (Ad)
Saudi oil company Aramco's half-year profits reach close to $88 billion after posting a 90% surge in second quarter
Average US gasoline price falls 45 cents to $4.10 per gallon
'Everyone's Got a Story of How the Healthcare System Has Fallen Short.' This Founder Is on a Mission to Change That.
The Financial Day of Reckoning Has Begun (Ad)
NASDAQ:ACHN

Achillion Pharmaceuticals - ACHN Stock Forecast, Price & News

Notice: This company has been marked as potentially delisted and may not be actively trading.
Add
Compare
Today's Range
$0.25
$0.25
50-Day Range
$6.76
$6.76
52-Week Range
$2.06
$7.01
Volume
N/A
Average Volume
8.44 million shs
Market Capitalization
$35.01 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
ACHN stock logo

About Achillion Pharmaceuticals (NASDAQ:ACHN) Stock

Achillion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small molecule drug therapies for immune system disorders. Its lead drug candidate is ACH-4471, an inhibitor of factor D that is Phase II clinical trials for patients with paroxysmal nocturnal hemoglobinuria (PNH) and C3 glomerulopathy/immune complex membranoproliferative glomerulonephritis. The company is also developing ACH-5228, a factor D inhibitor that is in Phase I clinical trials; and ACH-5548, a factor D inhibitor, which is in Phase I clinical trials for the treatment of PNH and other complement mediated diseases. It has license agreements with Ora, Inc. for the development and commercialization of ACH-702; and GCA Therapeutics, Ltd for elvucitabine, a nucleoside reverse transcriptase inhibitor for the treatment of hepatitis B infection and human immunodeficiency virus infection. The company was founded in 1998 and is based in New Haven, Connecticut.

Receive ACHN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Achillion Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ACHN Stock News Headlines

Alexion Pharmaceuticals Is On Sale
Achillion shareholders back Alexion takeover
Achillion's (ACHN) Danicopan Gets EMA's PRIME Tag for PNH
Achillion Pharmaceuticals EPS beats by $0.02
See More Headlines

Receive ACHN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Achillion Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

ACHN Company Calendar

Last Earnings
11/07/2019
Today
8/14/2022

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:ACHN
CUSIP
00448Q20
Fax
N/A
Employees
56
Year Founded
N/A

Profitability

Net Income
$-70,270,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$1.92 per share

Miscellaneous

Free Float
N/A
Market Cap
$35.01 million
Optionable
Optionable
Beta
1.59

Key Executives

  • Mr. Joseph Truitt (Age 54)
    Pres, CEO & Director
  • Ms. Martha E. Manning (Age 64)
    Exec. VP, Gen. Counsel & Corp. Sec.
  • Mr. Brian R. Di Donato (Age 52)
    CFO, SVP & Treasurer
  • Mr. Paul Firuta (Age 53)
    Exec. VP & COO
  • Dr. Kevin P. Malobisky
    Sr. VP of Regulatory Affairs, Quality & Compliance













ACHN Stock - Frequently Asked Questions

How were Achillion Pharmaceuticals' earnings last quarter?

Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN) announced its quarterly earnings data on Thursday, November, 7th. The biopharmaceutical company reported ($0.14) earnings per share for the quarter, topping the consensus estimate of ($0.16) by $0.02.

What other stocks do shareholders of Achillion Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Achillion Pharmaceuticals investors own include Chesapeake Energy (CHKAQ), Skyworks Solutions (SWKS), Madrigal Pharmaceuticals (MDGL), Noble (NE), ACADIA Pharmaceuticals (ACAD), Gilead Sciences (GILD), Eiger BioPharmaceuticals (EIGR), Iconix Brand Group (ICON), Celldex Therapeutics (CLDX) and Edap Tms (EDAP).

What is Achillion Pharmaceuticals' stock symbol?

Achillion Pharmaceuticals trades on the NASDAQ under the ticker symbol "ACHN."

What is Achillion Pharmaceuticals' stock price today?

One share of ACHN stock can currently be purchased for approximately $0.25.

How much money does Achillion Pharmaceuticals make?

Achillion Pharmaceuticals (NASDAQ:ACHN) has a market capitalization of $35.01 million. The biopharmaceutical company earns $-70,270,000.00 in net income (profit) each year or ($0.51) on an earnings per share basis.

How can I contact Achillion Pharmaceuticals?

Achillion Pharmaceuticals' mailing address is 300 GEORGE STREET, NEW HAVEN CT, 06511. The official website for the company is www.achillion.com. The biopharmaceutical company can be reached via phone at 203-624-7000.

This page (NASDAQ:ACHN) was last updated on 8/14/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.